Cadila Healthcare up 1% on tentative USFDA nod for blood sugar control drug


Share price of Cadila Healthcare gained 1.7 percent intraday Friday after it received tentative approval from the USFDA.

Zydus Cadila has received the tentative approval from the USFDA (US Food and Drug Administration) to market Linagliptin and Metformin Hydrochloride Tablets (US RLD-Jentadueto@Tablets), 2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/ 1,000 mg.

Leave a Reply

Your email address will not be published. Required fields are marked *